Get started
Author

Thomas Strakosch

Observed names: Strakosch, Thomas, T Strakosch
Observed institution: Cell and Gene Therapy Catapult
ORCID: 0009-0006-7206-9172
Observed ORCID: 0009-0006-7206-9172
OpenAlex ID: A5000065403
A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes
2026 · Thomas Strakosch, Shareen Forbes · Diabetic Medicine · 3
PDF
Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting
2025 · Rupesh Subash, Thomas Strakosch, et al. · Journal of Comparative Effectiveness Research · 1
PDF
EE88 Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study
2024 · C Spalding, B Mountford, et al. · Value in Health
PDF
Works count: 4
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type